Alkermes (ALKS) Expected to Announce Earnings on Thursday

Alkermes (NASDAQ:ALKS - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.32 per share and revenue of $307.53 million for the quarter. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. On average, analysts expect Alkermes to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Trading Up 1.3 %

Shares of ALKS traded up $0.38 during mid-day trading on Tuesday, reaching $28.29. 240,247 shares of the stock traded hands, compared to its average volume of 1,752,468. The company has a market cap of $4.66 billion, a price-to-earnings ratio of 13.03, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45. The firm has a fifty day moving average price of $31.76 and a 200 day moving average price of $30.43.

Analyst Ratings Changes

Several equities analysts recently commented on the company. UBS Group restated a "sector perform" rating on shares of Alkermes in a research report on Monday. Deutsche Bank Aktiengesellschaft boosted their price objective on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a report on Thursday, March 27th. HC Wainwright reaffirmed a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Royal Bank of Canada reissued an "underperform" rating on shares of Alkermes in a research note on Monday. Finally, StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $38.08.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. This trade represents a 71.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.40% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.